Brainstorm Cell Therapeutics (BCLI)

Brainstorm Cell Therapeutics (BCLI) Stock Price & Analysis


BCLI Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$1.09 - $4.70
Previous Close$2.94
Average Volume (3M)389.74K
Market Cap
Enterprise Value$117.31M
Total Cash (Recent Filing)$2.23M
Total Debt (Recent Filing)$3.68M
Price to Earnings (P/E)-4.5
Aug 15, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.66
Shares Outstanding39,408,554
10 Day Avg. Volume250,811
30 Day Avg. Volume389,743
Standard Deviation0.24
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-4.84
Price Target Upside75.44% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1



Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Insights

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Brainstorm Cell Therapeutics’s price range in the past 12 months?
Brainstorm Cell Therapeutics lowest stock price was $1.08 and its highest was $4.70 in the past 12 months.
    What is Brainstorm Cell Therapeutics’s market cap?
    Currently, no data Available
    When is Brainstorm Cell Therapeutics’s upcoming earnings report date?
    Brainstorm Cell Therapeutics’s upcoming earnings report date is Aug 15, 2023 which is in 75 days.
      How were Brainstorm Cell Therapeutics’s earnings last quarter?
      Brainstorm Cell Therapeutics released its earnings results on May 15, 2023. The company reported -$0.14 earnings per share for the quarter, beating the consensus estimate of -$0.165 by $0.025.
        Is Brainstorm Cell Therapeutics overvalued?
        According to Wall Street analysts Brainstorm Cell Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Brainstorm Cell Therapeutics pay dividends?
          Brainstorm Cell Therapeutics does not currently pay dividends.
          What is Brainstorm Cell Therapeutics’s EPS estimate?
          Brainstorm Cell Therapeutics’s EPS estimate is -$0.16.
            How many shares outstanding does Brainstorm Cell Therapeutics have?
            Brainstorm Cell Therapeutics has 39,408,554 shares outstanding.
              What happened to Brainstorm Cell Therapeutics’s price movement after its last earnings report?
              Brainstorm Cell Therapeutics reported an EPS of -$0.14 in its last earnings report, beating expectations of -$0.165. Following the earnings report the stock price went same 0%.
                Which hedge fund is a major shareholder of Brainstorm Cell Therapeutics?
                Currently, no hedge funds are holding shares in BCLI


                Brainstorm Cell Therapeutics Stock Smart Score

                The Brainstorm Cell Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                Learn more about TipRanks Smart Score

                Company Description

                Brainstorm Cell Therapeutics

                Brainstorm Cell Therapeutics, Inc. operates as a biotechnology company, which develops and commercializes adult stem cell therapeutic products. It focuses on utilizing the patients own bone marrow stem cells to generate neuron-like cells that may provide an effective treatment initially for amyotrophic lateral sclerosis, Parkinson's disease, multiple sclerosis and spinal cord injury. The company was founded on September 22, 2000 and is headquartered in New York, NJ.


                Top 5 ETFs holding BCLI

                Market Value
                Smart Score
                iShares Core S&P Total U.S. Stock Market ETF
                Up to five ETFs with an Outperform Smart Score that hold BCLI. The ETFs are listed according to market value of BCLI within the ETF


                Forecast EPS vs Actual EPS

                Similar Stocks
                Price & Change
                Atara Biotherapeutics

                Popular Stocks

                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis